About Ambrx
Ambrx is a company based in San Diego (United States) founded in 2003 was acquired by Johnson & Johnson in January 2024. Ambrx has raised $345.9 million across 6 funding rounds from investors including Fidelity Investments, Johnson & Johnson and Merck. The company has 79 employees as of December 31, 2022. Ambrx offers products and services including ARX788, ARX517, and ARX305. Ambrx operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter San Diego, United States
- Employees 79 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ambrx, Inc.
-
Annual Revenue
$7.4 M (USD)-1as on Dec 31, 2022
-
Net Profit
-$78 M (USD)-15as on Dec 31, 2022
-
EBITDA
-$76.4 M (USD)-19as on Dec 31, 2022
-
Total Equity Funding
$345.9 M (USD)
in 6 rounds
-
Latest Funding Round
$200 M (USD), Series E
Nov 09, 2020
-
Investors
Fidelity Investments
& 22 more
-
Employee Count
79
as on Dec 31, 2022
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ambrx
Ambrx offers a comprehensive portfolio of products and services, including ARX788, ARX517, and ARX305.
Targets cancer with stable, site-specific conjugation for effective treatment
Focuses on advanced prostate cancer through enhanced protein engineering
Develops conjugates for potential oncology applications in clinical settings
People of Ambrx
Unlock access to complete
Unlock access to complete
Funding Insights of Ambrx
Ambrx has successfully raised a total of $345.9M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $200 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ambrx
Ambrx has secured backing from 23 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Johnson & Johnson and Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Ambrx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ambrx
Investment portfolio details for Ambrx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ambrx
Detailed financials for Ambrx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ambrx Comparisons
Peer comparison for Ambrx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ambrx
Ambrx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Ambrx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ambrx
Complete news archive for Ambrx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ambrx
Ambrx was founded in 2003.
Ambrx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ambrx is a funded company, having raised a total of $345.9M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Ambrx is 79.
Annual revenue of Ambrx is $7.4M as on Dec 31, 2022.
Developer of Antibody-drug conjugates to treat cancers, metabolic disorders, and cardiovascular disorders. The company has developed Engineered Precision Biologics (EPBs) by using proprietary genetic code technology to produce antibody-drug conjugates (ADCs) and immuno-oncology conjugates (IOCs) for treating cancers. The product pipeline includes ARX788 an anti-HER2 ADC currently being studied in breast cancer, gastric cancer, and other solid tumors, ARX517 for prostate cancer, and more. They have developed immuno-oncology conjugates for NASH, heart failure, and prostate cancer.
Ambrx's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Ambrx offers ARX788, ARX517, and ARX305.
Ambrx has 23 investors. Key investors include Fidelity Investments, Johnson & Johnson, Merck, WuXi AppTec, and BlackRock.